Loading stock data…
Stevanato Group S.p.A. (STVN)
$20.32-0.19 (-0.93%)
Market ClosedLast close Sep 8
Stevanato Group S.p.A.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Stevanato Group S.p.A. in the Healthcare sector is trading at $20.32 with a market capitalization of $5.5B. Wall Street consensus targets $24.83 (11 analysts), implying a +22.2% move over the next 12 months. The stock is currently 27% below its 52-week high of $28.00, remaining 11.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +22.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | $280.04M↓ | $303.17M↓ | $346.48M↑ | $273.60M↓ | $302.00M |
| Gross Profit | $78.59M↓ | $88.50M↓ | $106.90M↑ | $75.20M↓ | $86.81M |
| Operating Income | $41.37M↓ | $52.72M↓ | $70.08M↑ | $38.80M↓ | $51.28M |
| Net Income | $29.70M↓ | $36.06M↓ | $47.55M↑ | $28.00M↑ | $22.96M |
Peer Comparison
JNJUNHPFE
Fundamentals
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.55B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
35.65
Beta
Defensive asset. Lower volatility than the S&P 500.
0.75
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.68%
Volume
Today's trading volume
205,626
Recent News
Stevanato Group (STVN) Trades A Subsidiary For Margin Gains And Growth
On August 4, Stevanato Group (NYSE:STVN) reported second-quarter revenue of €302.0 million, up 8% year over year, while also closing the sale of its California-based subsidiary, Balda C. Brewer Inc. The results paired steady growth in the company’s core drug containment and delivery business with a portfolio move that reshaped its bottom line for the […]
Riverwater Sees a Market Overreaction in Stevanato Group (STVN) After Oral GLP-1 Launches
Riverwater Partners, an investment management company, released its ‘Small Cap Strategy’ Q2 2026 investor letter. The letter can be downloaded here. The Small Cap Strategy underperformed the Russell 2000 in the second quarter as the benchmark experienced one of its strongest risk-on rallies in recent memory, although the strategy remained ahead year-to-date. The quarter was defined […]
Stevanato Group (STVN) Could Be 16% Undervalued Following Earnings And Guidance Update
What Stevanato Group’s latest earnings and guidance mean for investors Stevanato Group (STVN) has been in focus after its early August 2026 earnings report, which combined higher sales with lower net income, alongside updated full year revenue and earnings guidance. For the second quarter ended June 30, 2026, Stevanato Group reported sales of €302 million compared with €280.04 million a year earlier. Net income for the quarter was €22.96 million compared with €29.7 million in the prior year...
How Investors Are Reacting To Stevanato Group (STVN) Trimmed Guidance And New GLP-1 Pen Approvals
Stevanato Group S.p.A. recently reported past second-quarter 2026 results showing sales of €302 million with lower net income, slightly trimmed its full-year revenue guidance to €1.26–€1.28 billion, and outlined expected diluted EPS of €0.53–€0.55. At the same time, the company’s Alina pen injector platform secured European marketing authorizations for diabetes and weight-management combinations, highlighting Stevanato’s push into higher-value GLP-1 drug delivery solutions. We’ll now examine...
Stevanato Group (STVN) Stock Looks Cheap On Cash Flow But Pricey On Earnings
Stevanato Group stock has declined 34.6% over the past three years, and current checks send mixed valuation signals, with an intrinsic value estimate suggesting the shares trade at a discount while market multiples point to a richer price tag. Stevanato Group has fallen 34.6% over three years, which puts extra focus on whether the current share price still reflects the long term potential of its drug delivery and packaging business. Commercial progress for the Alina pen injector platform in...